What is CERS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.47B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CERS?

P/E (TTM) is n/a and 52-week range is $1.38 to $3.47 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CERS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CERS?

The company profile lists revenue (TTM) near $249M, net income (TTM) near -$680M, EPS (TTM) near -$0.03 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cerus Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Concord, California, US, 201.5M shares outstanding, ISIN US1570851014 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cerus Corp

$CERS

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 275 full-time employees. The firm is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Employees

275

Website

www.cerus.com/

IPO

1997-01-31

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)